Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ErVac01
- Development stage
- Preclinical
- Lead developer
- ErVimmune
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
**ErVac01** is an investigational, off-the-shelf heterologous viral-vector therapeutic cancer vaccine developed by ErVimmune. It encodes a multi-epitope set of tumor-associated antigens derived from human endogenous retroviruses, including HERV-K HML-2 Gag-derived epitopes, with adenovirus used for priming and modified vaccinia Ankara for boosting. The program is designed to induce antigen-specific cytotoxic CD8-positive T-cell responses against tumor cells presenting these HERV-derived epitopes while sparing normal cells, and is being advanced for cold tumors, initially triple-negative breast cancer and ovarian cancer. ([aacrjournals.org](https://aacrjournals.org/cancerimmunolres/article/13/2_Supplement/B123/751602/Abstract-B123-Preclinical-development-of-ErVac01-a))
- Other names
- Cancer Vaccine (Ovarian)
02
Targets
pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on ErVac01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ErVac01.